Cargando…
Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles
In the present study, for the first time, we released and assembled the particles of three major structural proteins of velogenic NDV (M, HN, and F glycoproteins) as a NDV-VLPs. The ElISA result of the cytokines of splenocyte suspension cells showed that IL2, IL10, TNF-α, and IFN- ˠ titers were sign...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582001/ https://www.ncbi.nlm.nih.gov/pubmed/37848725 http://dx.doi.org/10.1186/s13568-023-01617-9 |
_version_ | 1785122232283955200 |
---|---|
author | Firouzamandi, Masoumeh Helan, Javad Ashrafi Moeini, Hassan Soleimanian, Alireza Khatemeh, Saeed Hosseini, Seyed Davoud |
author_facet | Firouzamandi, Masoumeh Helan, Javad Ashrafi Moeini, Hassan Soleimanian, Alireza Khatemeh, Saeed Hosseini, Seyed Davoud |
author_sort | Firouzamandi, Masoumeh |
collection | PubMed |
description | In the present study, for the first time, we released and assembled the particles of three major structural proteins of velogenic NDV (M, HN, and F glycoproteins) as a NDV-VLPs. The ElISA result of the cytokines of splenocyte suspension cells showed that IL2, IL10, TNF-α, and IFN- ˠ titers were significantly higher (p ≤ 0.05) in mice that were immunized only with NDV-VLPs three times with a 10-day interval, in comparison to those that were immunized with NDV-VLPs twice in a 10-day interval and received a B1 live vaccine boost on the third interval. Flow cytometry results showed that CD8 + titers in the group that only received NDV-VLP was higher than other group. However, serum ELISA results did not show a significantly (p ≥ 0.05) higher NDV antibody titer in NDV-VLPs immunized mice compared to the boosted group. Besides, HI results of SPF chickens vaccinated with NDV-VLPs and boosted with B1 live vaccine were significantly (p ≤ 0.05) higher than those that only received NDV-VLPs. Interestingly, after challenging with NDV sub-genotype VII, all the chickens that were solely vaccinated with NDV-VLPs remained alive (six out of six), whereas two out of six chickens that were vaccinated with NDV-VLPs and also received the B1 live vaccine boost died. In conclusion, our results strongly indicated that the T-cell immune response in an NDV host is more important than the B-cell response. Also, the results of the present study revealed that to completely protect chickens against velogenic NDV strains, a vaccine comprising specific epitopes of velogenic strain is needed. |
format | Online Article Text |
id | pubmed-10582001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-105820012023-10-19 Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles Firouzamandi, Masoumeh Helan, Javad Ashrafi Moeini, Hassan Soleimanian, Alireza Khatemeh, Saeed Hosseini, Seyed Davoud AMB Express Original Article In the present study, for the first time, we released and assembled the particles of three major structural proteins of velogenic NDV (M, HN, and F glycoproteins) as a NDV-VLPs. The ElISA result of the cytokines of splenocyte suspension cells showed that IL2, IL10, TNF-α, and IFN- ˠ titers were significantly higher (p ≤ 0.05) in mice that were immunized only with NDV-VLPs three times with a 10-day interval, in comparison to those that were immunized with NDV-VLPs twice in a 10-day interval and received a B1 live vaccine boost on the third interval. Flow cytometry results showed that CD8 + titers in the group that only received NDV-VLP was higher than other group. However, serum ELISA results did not show a significantly (p ≥ 0.05) higher NDV antibody titer in NDV-VLPs immunized mice compared to the boosted group. Besides, HI results of SPF chickens vaccinated with NDV-VLPs and boosted with B1 live vaccine were significantly (p ≤ 0.05) higher than those that only received NDV-VLPs. Interestingly, after challenging with NDV sub-genotype VII, all the chickens that were solely vaccinated with NDV-VLPs remained alive (six out of six), whereas two out of six chickens that were vaccinated with NDV-VLPs and also received the B1 live vaccine boost died. In conclusion, our results strongly indicated that the T-cell immune response in an NDV host is more important than the B-cell response. Also, the results of the present study revealed that to completely protect chickens against velogenic NDV strains, a vaccine comprising specific epitopes of velogenic strain is needed. Springer Berlin Heidelberg 2023-10-17 /pmc/articles/PMC10582001/ /pubmed/37848725 http://dx.doi.org/10.1186/s13568-023-01617-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Firouzamandi, Masoumeh Helan, Javad Ashrafi Moeini, Hassan Soleimanian, Alireza Khatemeh, Saeed Hosseini, Seyed Davoud Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles |
title | Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles |
title_full | Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles |
title_fullStr | Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles |
title_full_unstemmed | Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles |
title_short | Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles |
title_sort | developing a vaccine against velogenic sub-genotype seven of newcastle disease virus based on virus-like particles |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582001/ https://www.ncbi.nlm.nih.gov/pubmed/37848725 http://dx.doi.org/10.1186/s13568-023-01617-9 |
work_keys_str_mv | AT firouzamandimasoumeh developingavaccineagainstvelogenicsubgenotypesevenofnewcastlediseasevirusbasedonviruslikeparticles AT helanjavadashrafi developingavaccineagainstvelogenicsubgenotypesevenofnewcastlediseasevirusbasedonviruslikeparticles AT moeinihassan developingavaccineagainstvelogenicsubgenotypesevenofnewcastlediseasevirusbasedonviruslikeparticles AT soleimanianalireza developingavaccineagainstvelogenicsubgenotypesevenofnewcastlediseasevirusbasedonviruslikeparticles AT khatemehsaeed developingavaccineagainstvelogenicsubgenotypesevenofnewcastlediseasevirusbasedonviruslikeparticles AT hosseiniseyeddavoud developingavaccineagainstvelogenicsubgenotypesevenofnewcastlediseasevirusbasedonviruslikeparticles |